What is Amenalief used for?

Amenalief is indicated for Herpes zoster, Recurrent herpes simplex.

Amenalief is developed by Maruho.

What development phase is Amenalief in?

Amenalief is FDA-approved (marketed).

What is the generic name of Amenalief?

AMENAMEVIR is the generic (nonproprietary) name of Amenalief.

Last reviewed 2026-04-20 · How we verify

Amenalief (AMENAMEVIR)

Maruho · FDA-approved approved Small molecule Quality 13/100

At a glance

Generic name	AMENAMEVIR
Sponsor	Maruho
Modality	Small molecule
Therapeutic area	Immunology
Phase	FDA-approved
First approval	2017

Approved indications

Herpes zoster
Recurrent herpes simplex

Common side effects

No common side effects on file.

Key clinical trials

Phase III Study of ASP2151 in Herpes Simplex Patients (PHASE3)
Open-label Study of ASP2151 in Herpes Simplex Patients (PHASE3)
Drug-Drug Interaction Study: ASP2151 and Ciclosporin (PHASE1)
Drug-Drug Interaction Study: ASP2151 and Montelukast (PHASE1)
Drug-Drug Interaction Study: ASP2151 and Ritonavir (PHASE1)
Drug-Drug Interaction Study: ASP2151 and Bupropion (PHASE1)
Drug-Drug Interaction Study: ASP2151 and Midazolam (PHASE1)
Phase III Study of ASP2151 in Herpes Zoster Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Amenalief CI brief — competitive landscape report
Amenalief updates RSS · CI watch RSS
Maruho portfolio CI